Cycle Pharmaceuticals proposes $466m acquisition of Vanda Pharmaceuticals
In a significant development within the pharmaceutical industry, UK-based Cycle Pharmaceuticals has offered to acquire Nasdaq-listed Vanda Pharmaceuticals in an all-cash transaction valued at $466 ... Read More
Vanda Pharmaceuticals rejects Future Pak’s acquisition offer
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) has officially declined the latest acquisition proposal from Future Pak, LLC (FP), citing substantial undervaluation and significant risk. The offer, ... Read More
Vanda Pharmaceuticals gets FDA orphan drug status for VPO-227 in cholera
Vanda Pharmaceuticals has secured orphan drug designation for VPO-227 from the US Food and Drug Administration (FDA) for the treatment of cholera. According to the ... Read More